Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

 
• By Sue Sutter

FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.

Gender dysphoria
The FDA is being pressed on treatments used off-label for gender dysphoria. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet